By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
No open-market selling at Zenas BioPharma, Inc. in the past year, which is unusual. Instead seven corporate insiders purchased about $17.3 million worth of ZBIO.
Kiselak Tomas (Director) made the biggest buy, worth around $3 million. C-suite participation is part of the picture here.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 4 of the last 7 full quarters. Big money check: 145 institutions held ZBIO as of Q2 2026, and more funds bought than sold.
Are insiders buying or selling ZBIO stock?
In the last 12 months Zenas BioPharma, Inc. insiders made open-market purchases worth about $17.3 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ZBIO?
The most recent open-market insider trade in ZBIO was filed on 2026-05-18.
How many institutions own ZBIO?
145 investment managers reported holding ZBIO in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ZBIO?
No congressional trades in ZBIO were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).